Comparison · NCT04437511-039cf943
Donanemab vs Placebo: Number or Participants With Anti-Donanemab Antibodies
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Donanemab vs Placebo: Number or Participants With Anti-Donanemab Antibodies. Trial comparisons, record NCT04437511-039cf943. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04437511-039cf943
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.874 | 0.849 | 0.895 | wilson | |
| Risk in group 2 | 0.0585 | 0.0444 | 0.0767 | wilson | |
| Risk difference, group 1 minus group 2 | 0.815 | 0.785 | 0.841 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 14.9 | 11.3 | 19.7 | log | |
| Odds ratio, group 1 over group 2 | 112 | 77.9 | 160 | log | |
| Number needed to treat, for one more participant with the outcome on Donanemab than on Placebo | 1.23 | 1.19 | 1.27 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Donanemab | Participants received 700 mg Donanemab Q4W x 3 doses, then 1400 mg Q4W given IV for up to 72 weeks | 693 | 793 | OG000 |
| Group 2 | Placebo | Participants received placebo given IV. | 48 | 821 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number or Participants With Anti-Donanemab Antibodies
- Description
- Number of participants with treatment-emergent positive Anti-Donanemab antibodies was summarized by treatment group.
- Time frame
- Baseline through Week 76
- Population
- All randomized participants who received at least one dose of study drug and had evaluable anti-drug antibody measurement.
Source ClinicalTrials.gov
Trial
- Title
- A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
- NCT number
- NCT04437511
- Phases
- PHASE3
- Conditions
- Alzheimer Disease
- Interventions
- Donanemab, Placebo
- Lead sponsor
- Eli Lilly and Company
- Results first posted
- 2024-05-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04437511?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04437511-039cf943